Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901835 | 1.00 | ALOX15 (0.40) | ALOX15BRD4LMNAALDH1A1HPGD | |
| SCHEMBL30411292 | 0.88 | BRD4 (0.41) | ALOX15BRD4LMNAALDH1A1HPGD | |
| SCHEMBL20766284 | 0.88 | BRD4 (0.41) | ALOX15BRD4LMNAALDH1A1HPGD | |
| SCHEMBL20766233 | 0.86 | CCR9 (0.47) | ALOX15LMNAALDH1A1HPGDHTT | |
| SCHEMBL29901843 | 0.86 | CCR9 (0.47) | ALOX15LMNAALDH1A1HPGDHTT | |
| SCHEMBL20766828 | 0.85 | ALOX15 (0.44) | ALOX15BRD4LMNAALDH1A1HSD17B10 | |
| SCHEMBL30411184 | 0.82 | GPR39 (0.47) | ALOX15BRD4LMNAALDH1A1HPGD | |
| SCHEMBL20766351 | 0.82 | GPR39 (0.47) | ALOX15BRD4LMNAALDH1A1HPGD | |
| SCHEMBL20779627 | 0.80 | ROCK2 (0.39) | LMNAALDH1A1HTTMAPTGAA | |
| SCHEMBL20766361 | 0.79 | PIK3CD (0.48) | ALOX15LMNAALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| CN-111542315-B | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-3691623-B1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| CN-111542315-A | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2020-08-14 | — | — | CN | disclosed |
| EP-3691623-A1 | BENZOSULFONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192865-B2 | Benzosulfonyl compounds | YAP1, TEAD2, TEAD1 | ALOX15 3108/4885BRD4 7/4885LMNA 2121/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | ALOX15 3548/4885BRD4 328/4885LMNA 2451/4885 |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | YAP1, TEAD2, TEAD1 | ALOX15 3108/4885BRD4 7/4885LMNA 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.